Switch theme
Sign up to access all valuation multiples
Balchem Corp is engaged in the development, manufacture, and marketing of specialty performance ingredients and products for various industries. The company's reportable segments are; Human Nutrition and Health, which generates maximum revenue, and provides human-grade choline nutrients and mineral amino acid chelated products through this segment for nutrition and health applications; Animal Nutrition and Health, which provides nutritional products derived from its microencapsulation and chelation technologies in addition to the essential nutrient choline chloride; and the Specialty Products segment includes re-packaging and distributing several performance gases and chemicals. Geographically, the company derives its key revenue from the United States and the rest from foreign countries.
1967
1.4K+
LTM Revenue $990M
LTM EBITDA $259M
$5.1B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Balchem has a last 12-month revenue (LTM) of $990M and a last 12-month EBITDA of $259M.
In the most recent fiscal year, Balchem achieved revenue of $954M and an EBITDA of $231M.
Balchem expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Balchem valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $990M | XXX | $954M | XXX | XXX | XXX |
| Gross Profit | $349M | XXX | $336M | XXX | XXX | XXX |
| Gross Margin | 35% | XXX | 35% | XXX | XXX | XXX |
| EBITDA | $259M | XXX | $231M | XXX | XXX | XXX |
| EBITDA Margin | 26% | XXX | 24% | XXX | XXX | XXX |
| EBIT | $196M | XXX | $183M | XXX | XXX | XXX |
| EBIT Margin | 20% | XXX | 19% | XXX | XXX | XXX |
| Net Profit | $140M | XXX | $128M | XXX | XXX | XXX |
| Net Margin | 14% | XXX | 13% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $140M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 31, 2025, Balchem's stock price is $152.
Balchem has current market cap of $5.0B, and EV of $5.1B.
See Balchem trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $5.1B | $5.0B | XXX | XXX | XXX | XXX | $4.47 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 31, 2025, Balchem has market cap of $5.0B and EV of $5.1B.
Balchem's trades at 5.4x EV/Revenue multiple, and 22.2x EV/EBITDA.
Equity research analysts estimate Balchem's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Balchem has a P/E ratio of 35.3x.
See valuation multiples for Balchem and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $5.0B | XXX | $5.0B | XXX | XXX | XXX |
| EV (current) | $5.1B | XXX | $5.1B | XXX | XXX | XXX |
| EV/Revenue | 5.2x | XXX | 5.4x | XXX | XXX | XXX |
| EV/EBITDA | 19.8x | XXX | 22.2x | XXX | XXX | XXX |
| EV/EBIT | 26.1x | XXX | 28.0x | XXX | XXX | XXX |
| EV/Gross Profit | 14.7x | XXX | n/a | XXX | XXX | XXX |
| P/E | 35.3x | XXX | 38.6x | XXX | XXX | XXX |
| EV/FCF | 34.9x | XXX | 35.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialBalchem's last 12 month revenue growth is 7%
Balchem's revenue per employee in the last FY averaged $0.7M, while opex per employee averaged $0.1M for the same period.
Balchem's rule of 40 is 30% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Balchem's rule of X is 43% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Balchem and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 7% | XXX | 7% | XXX | XXX | XXX |
| EBITDA Margin | 26% | XXX | 24% | XXX | XXX | XXX |
| EBITDA Growth | 5% | XXX | 11% | XXX | XXX | XXX |
| Rule of 40 | 30% | XXX | 31% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 43% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.7M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 7% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 2% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 16% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Borouge | XXX | XXX | XXX | XXX | XXX | XXX |
| Fertiglobe | XXX | XXX | XXX | XXX | XXX | XXX |
| Akzo Nobel | XXX | XXX | XXX | XXX | XXX | XXX |
| Avantium | XXX | XXX | XXX | XXX | XXX | XXX |
| DSM Firmenich | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Balchem acquired XXX companies to date.
Last acquisition by Balchem was XXXXXXXX, XXXXX XXXXX XXXXXX . Balchem acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Balchem founded? | Balchem was founded in 1967. |
| Where is Balchem headquartered? | Balchem is headquartered in United States of America. |
| How many employees does Balchem have? | As of today, Balchem has 1.4K+ employees. |
| Who is the CEO of Balchem? | Balchem's CEO is Mr. Theodore L. Harris. |
| Is Balchem publicy listed? | Yes, Balchem is a public company listed on NAS. |
| What is the stock symbol of Balchem? | Balchem trades under BCPC ticker. |
| When did Balchem go public? | Balchem went public in 1986. |
| Who are competitors of Balchem? | Similar companies to Balchem include e.g. Borouge, Fertiglobe, Akzo Nobel, Avantium. |
| What is the current market cap of Balchem? | Balchem's current market cap is $5.0B |
| What is the current revenue of Balchem? | Balchem's last 12 months revenue is $990M. |
| What is the current revenue growth of Balchem? | Balchem revenue growth (NTM/LTM) is 7%. |
| What is the current EV/Revenue multiple of Balchem? | Current revenue multiple of Balchem is 5.2x. |
| Is Balchem profitable? | Yes, Balchem is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Balchem? | Balchem's last 12 months EBITDA is $259M. |
| What is Balchem's EBITDA margin? | Balchem's last 12 months EBITDA margin is 26%. |
| What is the current EV/EBITDA multiple of Balchem? | Current EBITDA multiple of Balchem is 19.8x. |
| What is the current FCF of Balchem? | Balchem's last 12 months FCF is $147M. |
| What is Balchem's FCF margin? | Balchem's last 12 months FCF margin is 15%. |
| What is the current EV/FCF multiple of Balchem? | Current FCF multiple of Balchem is 34.9x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
